These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 15781338

  • 1. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ, Xue J, Corey SJ.
    Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
    [Abstract] [Full Text] [Related]

  • 2. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 3. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 4. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H, Reinhardt J, Zaborski M, Drexler HG.
    Leukemia; 2003 Jan 18; 17(1):120-4. PubMed ID: 12529668
    [Abstract] [Full Text] [Related]

  • 5. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
    Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A, Kiyoi H, Towatari M, Naoe T.
    Leukemia; 2007 Mar 18; 21(3):403-10. PubMed ID: 17230226
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
    Bruserud Ø, Hovland R, Wergeland L, Huang TS, Gjertsen BT.
    Haematologica; 2003 Apr 18; 88(4):416-28. PubMed ID: 12681969
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug 18; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E, Barbarroja N, Torres LA, Buendía P, Velasco F, Dorado G, Torres A, López-Pedrera C.
    Hematol Oncol; 2007 Mar 18; 25(1):30-7. PubMed ID: 17128418
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.
    Mitina O, Warmuth M, Krause G, Hallek M, Obermeier A.
    Ann Hematol; 2007 Nov 18; 86(11):777-85. PubMed ID: 17668209
    [Abstract] [Full Text] [Related]

  • 13. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Komeno Y, Kurokawa M, Imai Y, Takeshita M, Matsumura T, Kubo K, Yoshino T, Nishiyama U, Kuwaki T, Kubo K, Osawa T, Ogawa S, Chiba S, Miwa A, Hirai H.
    Leukemia; 2005 Jun 18; 19(6):930-5. PubMed ID: 15815726
    [Abstract] [Full Text] [Related]

  • 14. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, Tang Y, Shephard L, Goldbeck C, Oei Y, Ye H, Aukerman SL, Heise C.
    Clin Cancer Res; 2005 Jul 15; 11(14):5281-91. PubMed ID: 16033847
    [Abstract] [Full Text] [Related]

  • 15. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G.
    Exp Hematol; 2007 Apr 15; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [Abstract] [Full Text] [Related]

  • 16. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q, Nishiuchi R, Kitamura T, Kersey JH.
    Leukemia; 2005 Sep 15; 19(9):1605-12. PubMed ID: 16034464
    [Abstract] [Full Text] [Related]

  • 17. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.
    Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T.
    Oncogene; 2002 Apr 11; 21(16):2555-63. PubMed ID: 11971190
    [Abstract] [Full Text] [Related]

  • 18. Expression of the flt3 receptor and its ligand on hematopoietic cells.
    Brasel K, Escobar S, Anderberg R, de Vries P, Gruss HJ, Lyman SD.
    Leukemia; 1995 Jul 11; 9(7):1212-8. PubMed ID: 7630197
    [Abstract] [Full Text] [Related]

  • 19. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.
    Clin Cancer Res; 2005 Feb 15; 11(4):1416-24. PubMed ID: 15746041
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.